Invasive fungal infections – Page 5

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, especially in patients whose immune systems are weakened. The researchers found that while most hospitals have good access to testing and antifungal medications, some important tests are still missing, and many hospitals send samples to other facilities for testing, which can delay treatment. Since this region has unusually high rates of fungal infections that resist common antifungal drugs, improving access to advanced diagnostic tests is crucial for patient survival.

Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistant Lomentospora prolificans infection in a child

mycolabadmin

A young girl contracted a dangerous drug-resistant fungal infection in her knee after an injury, which failed to respond to standard antifungal treatments. Doctors obtained special access to an experimental antifungal drug called olorofim through a compassionate use program. The child showed improvement within two weeks and was completely cured after six months of treatment with no signs of the infection returning two years later, making this the first successful case of this new drug being used in a child.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

This study reviewed clinical trials comparing a newer antifungal drug called isavuconazole with other commonly used antifungal medications for treating serious fungal infections, particularly in patients with weakened immune systems. The research found that isavuconazole works just as well as other antifungal drugs but may have fewer side effects, especially liver problems. When compared directly with voriconazole, isavuconazole showed fewer drug-related side effects overall, making it a good alternative option for patients who cannot tolerate other antifungal treatments.

Candida vulturna, the Next Fungal Menace? A Narrative Review

mycolabadmin

Candida vulturna is a newly identified fungus that causes serious bloodstream infections, particularly in newborns and hospitalized patients in tropical regions. Unlike many common fungal infections, it resists several antifungal medications, though it remains susceptible to certain antibiotics called echinocandins. Scientists have documented 94 cases worldwide, including three hospital outbreaks, and the infection has a relatively low death rate of 18%. Accurate identification requires genetic testing since standard hospital laboratory tests often misidentify this pathogen.

Incidence and Risk Factors for Invasive Fungal Infection in Patients with Hematological Malignancies at a Tertiary Hospital in Malaysia

mycolabadmin

This study examined fungal infections in cancer patients with blood disorders in a Malaysian hospital. Researchers found that about 7.6% of patients developed serious fungal infections, mainly from Candida species. Using antifungal medications to prevent infection significantly reduced the risk, though some patients still developed infections while taking preventive medications. The findings highlight the importance of appropriate antifungal treatment strategies in managing these vulnerable patients.

Fungal infections in burn patients: The rise of Fusarium as the most prevalent in a burn center in Mexico City

mycolabadmin

Burn patients are at high risk for serious fungal infections that can cause death. This study from a Mexican burn hospital found that a fungus called Fusarium was the most common cause of these infections, affecting over half of patients with fungal infections. This finding differs from other parts of the world where Aspergillus is usually most common, suggesting that Mexican burn patients face unique fungal threats that doctors should watch for carefully.

Fungi under fire: diagnostic capacities and antifungal availability in Peruvian healthcare facilities

mycolabadmin

This study examined how well Peruvian hospitals can diagnose and treat serious fungal infections across the country. Researchers surveyed 54 healthcare centers and found that while basic fungal tests are available everywhere, advanced diagnostic tools and certain antifungal medications are mostly limited to the capital city of Lima. The research identifies major gaps in care that need to be addressed to help more patients survive these serious infections.

Invasive Saprochaete capitata Infection in an Immunocompromised Patient With Acute Myeloid Leukemia: A Case Report

mycolabadmin

A 46-year-old man with blood cancer developed a serious fungal infection caused by Saprochaete capitata during chemotherapy. This rare but dangerous fungus was found in his blood and lungs, causing fever and breathing problems. The patient was successfully treated with a combination of two antifungal medications and fully recovered, though this infection typically has a high death rate.

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied patients with multiple myeloma who received a new type of cancer treatment called BCMA CAR-T cell therapy. While this powerful therapy can sometimes increase infection risk, the study found that serious fungal infections occurred in only a small percentage of patients (1.7%). However, when these fungal infections did occur, they were often severe and potentially life-threatening, particularly in patients who experienced significant side effects from the therapy.

Rhino-orbital-cerebral mucormycosis in diabetic ketoacidosis: A classic clinical presentation still unknown in Senegal

mycolabadmin

A young woman in Senegal with uncontrolled diabetes developed a serious fungal infection affecting her eye and brain caused by Rhizopus oryzae. Despite showing classic warning signs like swelling and tissue death, the infection was not diagnosed quickly enough, and the necessary antifungal medication (amphotericin B) was not available, resulting in her death within three days. This case highlights how invasive fungal infections are underrecognized and undertreated in Africa due to limited laboratory capacity and drug availability.

Research Topic: Invasive fungal infections